Price gouging appears to be a growing problem in the UK, where price tags for generic versions of more than a dozen cancer medicines rose between 100 percent and 1,100 percent from 2011 to 2016, even though the drugs can be made for very little, according to a new analysis by UK researchers.

The researchers found there was often a lack of competition for 14 off-patent medicines and, as a result, the outlays are straining the UK’s National Health Service at a time when cancer drugs are being rationed. One example cited was the busulfan chemotherapy for leukemia, which rose 1,143 percent during that five-year period. The analysis was presented over the weekend at the European Cancer Congress in Amsterdam.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy